about
Optimizing Research Methods to Understand HIV-Exposed Uninfected Infant and Child Morbidity: Report of the Second HEU Infant and Child Workshop.Systematic review and meta-analysis of the adolescent HIV continuum of care in South Africa: the Cresting Wave.Molecular Characterization of Corynebacterium diphtheriae Outbreak Isolates, South Africa, March-June 2015An update on the HIV treatment cascade in children and adolescents.An isolated outbreak of diphtheria in South Africa, 2015.Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial.Tuberculosis in HIV-infected South African children with complicated severe acute malnutrition.Bacterial infections in HIV-infected children admitted with severe acute malnutrition in Durban, South Africa.Donovanosis causing lymphadenitis, mastoiditis, and meningitis in a child.Defining Study Outcomes That Better Reflect Individual Response to Treatment.Population Pharmacokinetics of Lopinavir in Severely Malnourished HIV Infected Children and the Effect on Treatment Outcomes.Priorities for Decreasing Morbidity and Mortality in Children With Advanced HIV Disease.Qualitative situational analysis of palliative care for adolescents with cancer and HIV in South Africa: healthcare worker perceptionsUnmet needs of high-risk mothers reduce success of antiretroviral treatment in HIV-infected infantsHIV viral load testing coverage and timeliness after implementation of the wellness anniversary in a paediatric and adolescent HIV clinic in KwaZulu-Natal, South AfricaAcceptability of short text messages to support treatment adherence among adolescents living with HIV in a rural and urban clinic in KwaZulu-NatalCurrent perspectives on paediatric HIV management from the Mexico International Aids Society Conference, 2019Increasing Diagnostic Uncertainties in Children With In Utero HIV InfectionAcceptability and Feasibility of Using Raltegravir Oral Granules for the Treatment of Neonates in a Low-resource SettingLong-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research prioritiesPopulation pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virus-infected children in relation to treatment outcomesImpact of Shifts to Birth Testing on Early Infant Diagnosis Program Outcomes in KwaZulu-Natal, South AfricaImpact of routine birth early infant diagnosis on neonatal HIV treatment cascade in eThekwini district, South Africa
P50
Q37474922-14152459-BD69-4E46-84E2-55C24C04CE16Q37659742-7A791210-28BC-49FA-A18F-6D199D465D07Q38372999-E25D2FC1-5F02-49A1-9074-E46D87147996Q38583483-7AA2B594-F3B3-4137-AE5A-E307C6884A88Q38800043-F1CC4C4A-D995-4B04-8602-C9C1D5FDE334Q38853723-359ED9BC-E59D-4B46-9800-2222C3346E8AQ38861148-B1C2AD8A-266E-48B2-BAA4-7A6911BF570CQ40626211-6FD4C92C-B6CB-41BB-8C5E-7D80F34B5875Q41133893-C6EC665E-20B0-45CE-9F4C-A7BDFA0D19E3Q47571203-122CE0A3-CCD3-46AC-9859-3283998C28FEQ49949305-AF7A97A8-B673-4DD5-8819-AB5FE9D9F235Q54260534-24F69726-A322-45C0-81DC-4A0D49C2279BQ61808891-B64D6CC9-4F5B-42A1-8DF3-0569DF8B1379Q70973563-DE176FF0-BE4A-4CC5-8B37-5888D676F144Q90219672-54BC5396-119D-427F-9791-45F4ACD69975Q90734102-03EA411C-C06E-47CB-9703-6F0449F76C06Q91345965-BCA175FA-9F13-409D-A2B9-A94470CFC059Q91598958-18ED5617-2EA2-4D08-A0A5-AC55D34F9B3CQ91799667-27456680-95A1-4B5A-B43D-73291ACE7248Q91899040-7C01FAC3-71B5-422A-9513-CEC037BE67B7Q92372076-46CF6CEF-49BB-4D2F-995E-98845036BCB5Q92708788-CE78580F-D01F-454A-B12B-50637069BE7DQ96346160-894E42E1-FD81-459B-9ED2-5856152587F5
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
Moherndran Archary
@ast
Moherndran Archary
@en
Moherndran Archary
@es
Moherndran Archary
@nl
type
label
Moherndran Archary
@ast
Moherndran Archary
@en
Moherndran Archary
@es
Moherndran Archary
@nl
prefLabel
Moherndran Archary
@ast
Moherndran Archary
@en
Moherndran Archary
@es
Moherndran Archary
@nl
P1153
56725634600
P31
P496
0000-0003-3082-9234